Logo

PharmaShots Weekly Snapshots (May 23 - 27, 2022)

Share this
PharmaShots Weekly Snapshots (May 23 - 27, 2022)

PharmaShots Weekly Snapshots (May 23 - 27, 2022)

Exelixis to Presents Results of Cabometyx (cabozantinib) in P-II Trial for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

Published: May 27, 2022 | Tags: Exelixis, Cabometyx, cabozantinib, P-II Trial, Head, Neck, Squamous Cell Carcinoma, ASCO, 2022

ManaMed’s ManaSport Ultrasound Therapy Class II Device Receives the US FDA’s Approval for the Treatment of Chronic Pain

Published: May 27, 2022 | Tags: ManaMed, ManaSport, Ultrasound Therapy Class II Device, US, FDA, Approval, Chronic Pain

AbbVie Published Results of Rinvoq (upadacitinib) & Skyrizi (risankizumab) in Multiple P-III Induction and Maintenance Studies for UC & CD in The Lancet

Published: May 27, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, Skyrizi, risankizumab, P-III, Induction, Maintenance Studies, UC & CD

BMS to Present Results of Breyanzi (lisocabtagene maraleucel) in P-II (PILOT) Study for R/R Large B-cell Lymphoma at ASCO 2022

Published: May 27, 2022 | Tags: BMS, Breyanzi, lisocabtagene maraleucel, P-II, PILOT Study, Large B-cell Lymphoma, ASCO, 2022

Pfizer’s Ervogastat + Clesacostat Receives the US FDA’s Fast Track Designation for the Treatment of Non-Alcoholic Steatohepatitis

Published: May 27, 2022 | Tags: Pfizer, Ervogastat, Clesacostat, US, FDA, Fast Track Designation, Non-Alcoholic Steatohepatitis

Takeda and Seagen to Present Results of Adcetris (brentuximab vedotin) for the Treatment of Advanced Hodgkin Lymphoma at ASCO 2022

Published: May 27, 2022 | Tags: Takeda, Seagen, Adcetris, brentuximab vedotin, Hodgkin Lymphoma, ASCO, 2022

Legend’s Carvykti (ciltacabtagene autoleucel) Receives the EC’s Approval for the Treatment of Relapsed and Refractory Multiple Myeloma

Published: May 26, 2022 | Tags: Legend, Carvykti, ciltacabtagene autoleucel, EU, Relapsed and Refractory Multiple Myeloma

GrowLab Reports Results of Comacadine for the Treatment of Diabetes Mellitus

Published: May 26, 2022 | Tags: GrowLab, Comacadine, Diabetes Mellitus

Servier’s Tibsovo (ivosidenib) Receives the US FDA's Approval for the Treatment of IDH1-mutated Acute Myeloid Leukemia

Published: May 26, 2022 | Tags: Servier, Tibsovo, ivosidenib, US FDA, IDH1-mutated Acute Myeloid Leukemia

Targan Secures Funding from Mountain Group Partners and NovaQuest Capital Management to Commercialize Poultry Vaccination and Gender Identification System

Published: May 26, 2022 | Tags: Targan, Funding, Mountain Group Partners, NovaQuest Capital Management, Poultry Vaccination, Gender Identification System

KaliVir and Roche Enters into a Global Licensing Agreement to Discover, Develop and Commercialize Novel Oncolytic Vaccinia Viruses

Published: May 26, 2022 | Tags: KaliVir, Roche, Global Licensing Agreement, Novel Oncolytic Vaccinia Viruses, VET Platform

Aeterna Zentaris and Consilient Health Launches Ghryvelin (macimorelin) Across the EU for the Diagnosis of Adult Growth Hormone Deficiency

Published: May 26, 2022 | Tags: Ghryvelin, macimorelin, Aeterna, Consilient Health, Novo Nordisk, Europe, Adult Growth Hormone Deficiency

PharmaTher Entered into a Development Agreement with CCBIO to Develop and Commercialize Wearable Ketamine Delivery Device

Published: May 25, 2022 | Tags: PharmaTher, CCBIO, Wearable Ketamine Delivery Device

Endotronix Presents Results of Cordella PA Pressure Sensor System in (SIRONA 2) for NYHA Class III Heart Failure at ESC 2022

Published: May 25, 2022 | Tags: Endotronix, Cordella PA Pressure Sensor System, SIRONA 2, NYHA Class III Heart Failure, ESC, 2022

Janssen Presents Results of Tremfya (guselkumab) in P-II (GALAXI 1) Trial and Long-Term Safety Profile for Stelara (ustekinumab) to Treat IBD at DDW 2022

Published: May 25, 2022 | Tags: Janssen, Tremfya, guselkumab, P-II, GALAXI 1 Trial, Stelara, ustekinumab, IBD, DDW, 2022

Junshi Biosciences Reports Results of VV116 (JT001) in the P-III Registrational Trial for Early Treatment of COVID-19 in High Risk Patients

Published: May 25, 2022 | Tags: Junshi Biosciences, VV116, JT001, P-III, Registrational Trial, COVID-19

Everest Licensing Partner Pfizer Presents Results of Etrasimod in P-III (ELEVATE UC 12 & 52) Studies for the Treatment of Ulcerative Colitis at DDW 2022

Published: May 25, 2022 | Tags: Everest, Pfizer, Etrasimod, P-III, ELEVATE UC 12, 52, Studies, Ulcerative Colitis, DDW, 2022

CASI Entered into a Sublicense Agreement with Tianshi for CID-103 to Treat Autoimmune Diseases

Published: May 25, 2022 | Tags: CASI, Sublicense Agreement, Tianshi, CID-103, Autoimmune Diseases

Ocugen’s NeoCart Receives the US FDA Regenerative Medicine Advanced Therapy Recognition for the Treatment of Knee Injury in Adults

Published: May 24, 2022 | Tags: Ocugen, NeoCart, US FDA, Regenerative Medicine Advanced Therapy, RMAT, Knee Injury, Lesions, Knee Cartilage

UCB Reports Data of Bimekizumab in P-III (BE MOBILE 1) and (BE MOBILE 2) Studies for the Treatment of Axial Spondyloarthritis (axSpA) and Ankylosing Spondylitis (AS)

Published: May 24, 2022 | Tags: UCB, Bimekizumab, P-III, BE MOBILE 1, BE MOBILE 2, Axial Spondyloarthritis, Ankylosing Spondylitis

Lilly Reports Clinical Remission in 50% of Patients Treated with Mirikizumab in P-III (LUCENT-2) Trial for the Treatment of Ulcerative Colitis

Published: May 24, 2022 | Tags: Lilly, Clinical Remission, Mirikizumab, P-III, LUCENT-2, Ulcerative Colitis

ImmuntyBio Submits Biologics License Application for N-803 + BCG to Treat BCG-unresponsive NMIBC CIS

Published: May 24, 2022 | Tags: ImmuntyBio, Biologics License Application, N-803, BCG, BCG-unresponsive NMIBC CIS, Bladder Cancer

Janssen Publishes the Results of Two Studies with Xarelto (rivaroxaban) + Aspirin (Acetylsalicylic Acid) in Patients with CAD and/or PAD

Published: May 24, 2022 | Tags: Bayer, Janssen, Xarelto, rivaroxaban, Aspirin, Acetylsalicylic Acid, CAD, PAD

Innoviva Entered into a Definitive Merger Agreement with Entasis Therapeutics

Published: May 24, 2022 | Tags: Innoviva, Entasis Therapeutics, SUL-DUR, Merger, Acquisition, Infectious Disease

Alnylam Presents 18-Month Results in the P-III (HELIOS-A) Study of Vutrisiran for hATTR Amyloidosis with Polyneuropathy at ESC 2022

Published: May 23, 2022 | Tags: Alnylam, Exploratory Cardiac Endpoints, P-III, HELIOS-A Study, Vutrisiran, hATTR, Amyloidosis, Polyneuropathy, ESC, 2022

Merck Receives CHMP Positive Opinion of Keytruda (pembrolizumab) as Adjuvant Treatment for Stage IIB or IIC Melanoma

Published: May 23, 2022 | Tags: Merck, CHMP, Keytruda, pembrolizumab, Stage IIB, IIC, Melanoma

Regeneron Presents Results of Evkeeza (evinacumab) in P-III Trial for Homozygous Familial Hypercholesterolemia in Children at EAS 2022

Published: May 23, 2022 | Tags: Regeneron, Evkeeza, evinacumab, P-III Trial, Homozygous Familial Hypercholesterolemia, EAS, 2022

Kala Entered into Definitive Agreement with Alcon to Acquire Eysuvis and Inveltys for the Treatment of Acute Dry Eye Disease

Published: May 23, 2022 | Tags: Kala, Alcon, Acquire, Eysuvis, Inveltys, Acute Dry Eye Disease

Eli Lilly and Incyte Receive CHMP Positive Opinion of Olumiant (baricitinib) for the Treatment of Adults with Severe Alopecia Areata

Published: May 23, 2022 | Tags: Eli Lilly, Incyte, CHMP, Olumiant, baricitinib, Alopecia Areata

Bridgebio and Affiliate Phoenix Tissue Repair Presents Results of PTR-01 in P-II Trial for Recessive Dystrophic Epidermolysis Bullosa at SID 2022

Published: May 23, 2022 | Tags: Bridgebio Pharma, PTR-01, P-II Trial, Recessive Dystrophic Epidermolysis Bullosa, SID, 2022

Related Post: PharmaShots Weekly Snapshots (May 16 - 20, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions